Cycle on Jul 13, 2026

I am starting the research cycle by listing the existing threads to see if there are any active questions, watches, or catalysts that we need to address or monitor. I will also query the market views for the core companies: Eli Lilly (LLY), Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR) to check their current financial metrics and recent corporate developments.

I will now pull the market views for our core public companies: Eli Lilly (LLY), Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). This will provide current financial metrics, valuations, and recent news for these companies.

I will now query the remaining core companies: Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). I'll execute these calls to get their market views.

I will now fetch the market views for Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR).

Now let's check Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR).

I will now fetch the market view for GPCR (Structure Therapeutics).

The threads listed a few critical watches: 1. **Medicare GLP-1 Bridge Program Official Launch** set for July 1, 2026. This date has passed (current date is July 13, 2026). I need to check if this program launched, what the details are, and if we should record an event. 2. **Viking Therapeutics' exploratory Phase 1 maintenance study of VK2735** and **VK3019** (its new dual amylin and calcitonin receptor agonist) which recently initiated Phase 1 trials (news from July 9/11, 2026). 3. **Novo Nordisk's CagriSema device study withdrawal** (news from July 9, 2026) and collaboration with **Vivani Medical** on a semaglutide implant (news from July 12, 2026). 4. **Structure Therapeutics corporate presentations / Morgan Stanley Healthcare Conference** (news from July 6/9, 2026). 5. **Amgen's tax dispute** or **MariTide** pipeline updates. Let's do some targeted web searches on these events to verify the details and write highly-informed notes. First, let's search for "Medicare GLP-1 Bridge Program" or similar terms to see what happened around July 1, 2026. Then let's search for Novo Nordisk's CagriSema withdrawal and the Vivani Medical semaglutide implant. Then let's check Viking's new VK3019. This is a lot of extremely fresh news (July 2026). Let's do a search.

The Medicare GLP-1 Bridge program has indeed launched on July 1, 2026. I will fetch the CMS newsroom press release or the KFF report to get the exact details. Let's fetch the KFF report (or CMS newsroom) to understand how it's going, who is eligible, and any initial pharmacy/billing details. Let's search specifically for news on the launch in July 2026 to see if there are any initial implementation issues, patient uptake numbers, or pharmacy network details.

Let's fetch the AJMC article on "Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?" and the CMS press release on "CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications". First, I'll fetch the AJMC article, then the CMS press release.

This is an excellent, detailed article that answers many questions. Let's record the event for the "Medicare GLP-1 Bridge Program Official Launch" watch which was set for July 1, 2026. This watch has indeed fired (the program launched on July 1, 2026, and was extended to December 31, 2027, rather than the initial 6 months). Let's call `record_event` on the thread `019eee6b-ebce-733a-b5e9-20de6bc09693` first. Then we'll resolve it with `resolve_thread`. But before calling resolve, let's write a note about this. Let's do some more searches to gather information on: 1. Novo Nordisk's CagriSema device study withdrawal and Vivani Medical semaglutide implant. 2. Viking Therapeutics' new dual amylin/calcitonin receptor agonist VK3019. 3. Structure Therapeutics oral aleniglipron Phase 3 trial initiation (which is scheduled for Q3 2026). Let's search for "Novo Nordisk CagriSema device study withdrawal July 2026" and "Novo Nordisk Vivani Medical semaglutide implant".

Let's fetch the Globe and Mail press release / article: `https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/3227366/novo-nordisk-halts-device-study-for-cagrisema-what-it-means-for-nvo-investors/` or `https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/3227366/novo-nordisk-halts-device-study-for-cagrisema-what-it-means-for-nvo-investors/` to understand the CagriSema device study withdrawal. Let's fetch the first one.

Okay, the CagriSema study that was withdrawn was specifically a device comparability study (comparing two injection devices for the combination drug CagriSema). This does not mean the CagriSema drug program itself is canceled or delayed, but rather that this single device trial was withdrawn. Now let's search for "Viking Therapeutics VK3019 July 2026" to see what this new dual amylin and calcitonin receptor agonist is about and its Phase 1 trial initiation.

This is excellent. Let's fetch the press release: `https://ir.vikingtherapeutics.com/2026-06-24-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Novel-Amylin-Receptor-Agonist-VK3019-in-Healthy-Adults` to read the exact details of the VK3019 initiation.

This is incredibly detailed and useful! Let's examine the Viking pipeline updates: 1. **VK3019 (Amylin/Calcitonin receptor agonist / DACRA)**: Phase 1 clinical trial (SAD study) was initiated on **June 24, 2026** in healthy adults with BMI >= 30. 2. **VK2735 (SC GLP-1/GIP agonist)**: Currently conducting Phase 3 **VANQUISH** studies (VANQUISH-1 in obesity, VANQUISH-2 in obesity + type 2 diabetes). These are 78-week studies. 3. **VK2735 (Oral)**: Viking plans to initiate a Phase 3 trial to evaluate oral VK2735 for obesity and overweight later this year (2026). 4. **VK2735 Maintenance Dosing Study**: Exploratory Phase 1 study initiated in October 2025. Results are expected in **3Q26**. This perfectly maps to our Viking watches: - "Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation" (scheduled for late 2026). This is ongoing. - "Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout" (scheduled for Q3 2026). This is also ongoing. Let's search for "Novo Nordisk Vivani Medical semaglutide implant July 2026" to see what this collaboration is about. This is a fascinating development for Novo Nordisk. Let's do a web search.

Let's fetch the Vivani press release: `https://investors.vivani.com/investors/news-events/press-releases/detail/220/vivani-medical-enters-into-agreement-with-novo-nordisk-to` to see the details of this agreement. This is a very interesting piece of evidence.

This is a fantastic development! Novo Nordisk has signed an agreement with Vivani Medical to evaluate **NPM-139**, a miniature, ultra long-acting semaglutide implant that uses Vivani's NanoPortal technology for chronic weight management. The implant is designed for once- or twice-yearly administration. Let's check if there is any other news on Amgen's tax court ruling or Amgen's MariTide pipeline progress. Let's do a search.

Let's search for "Amgen IRS tax dispute July 2026" or "Amgen tax court ruling 2026". These are crucial details to see if any tax court updates have occurred, as that was one of the watches.

The Law360 article "Top International Tax Cases To Watch In 2nd Half Of 2026" (published recently, as of July 2026) indicates that the Amgen litigation continues into the second half of 2026. This confirms that the Amgen tax court ruling watch is still ongoing and active, as expected. Let's write our findings. First, we will write a note on the **Medicare GLP-1 Bridge Program Launch**, which is a major commercial update. We have excellent data from AJMC, KFF, and CMS. Let's look at the existing notes on this topic to see if we can reuse any slugs, or if we should create new ones. The relevant prior findings are: - `glp1-competitive-landscape-ada-2026` - `employer-glp1-coverage-cuts-cigna` - `glp1-impact-medtech-bariatric-surgery-decline` - `structure-therapeutics-aleniglipron-access-ii-results` - `eli-lilly-q1-2026-blowout-cvs-formulary-victory` Wait! Is there an existing note on Medicare/BALANCE or the Bridge program? Let's check `read_notes` to see if there are other notes we didn't see in the semantic search.

Perfect! We have several notes we can update: 1. `medicare-glp-1-bridge-program-50-copay` can be updated with details of the official launch on July 1, 2026, the enrollment estimates (KFF vs Lilly/CMS), the Humana central processing, the extension to December 31, 2027, and the delay of the BALANCE model. 2. `viking-therapeutics-oral-vk2735-phase-2-venture` can be updated with the initiation of the Phase 1 trial for the novel dual amylin/calcitonin receptor agonist **VK3019** on June 24, 2026. 3. We can write a new note or update `novo-nordisk-cagrisema-zenagamtide-ada-2026-data` or create a new note on the Novo Nordisk collaboration with Vivani Medical for the semaglutide implant and the withdrawal of the CagriSema device study. Let's look at `novo-nordisk-cagrisema-zenagamtide-ada-2026-data` or create a new note on Novo Nordisk's long-acting pipeline developments (implant + CagriSema device study). A new note or updating an existing one: Novo Nordisk's long-term pipeline strategy is a perfect subject. Let's update `novo-nordisk-cagrisema-zenagamtide-ada-2026-data` or create a separate note for the long-acting/implant developments. Since the implant is a new theme, let's create a new note `novo-nordisk-ultra-long-acting-implant-vivani` or update the competitive landscape. Let's see if there's a better slug. "Novo Nordisk's Next-Gen Pipeline: CagriSema Device Study Withdrawal and Vivani Semaglutide Implant Agreement" makes sense. Let's create `novo-nordisk-next-gen-pipeline-implant-cagrisema`. Let's do the updates. First, let's update `medicare-glp-1-bridge-program-50-copay` to document the actual launch details as of July 1, 2026. We will use the exact quotes and figures from the AJMC article and KFF/CMS reports we fetched. Let's write the note.

Now I will record the event and resolve the thread for the Medicare GLP-1 Bridge Program Launch watch. Let's call `record_event` with `thread_id: 019eee6b-ebce-733a-b5e9-20de6bc09693`. This is a `one_shot` watch, so `resolves: true`. Let's do that.

Now I will call `resolve_thread` to close the thread for the Medicare GLP-1 Bridge program.

Now let's update Viking Therapeutics' note (`viking-therapeutics-oral-vk2735-phase-2-venture`) to document the initiation of the Phase 1 trial for **VK3019** on June 24, 2026. This is a key pipeline expansion into dual amylin/calcitonin receptor agonists (DACRAs), which directly competes with Novo Nordisk's amylin pipeline (cagrilintide). Let's write this update.

Now let's write a new finding on Novo Nordisk's next-generation pipeline developments. This will capture: 1. The **Vivani Medical agreement** signed on **July 7, 2026**, where Novo Nordisk will evaluate **NPM-139**, a miniature, ultra long-acting semaglutide implant designed for once- or twice-yearly administration. 2. The **CagriSema device study withdrawal** on **July 7, 2026** (a placebo-controlled comparability study comparing two injectable device presentations of CagriSema), which slightly shifts short-term focus but does not detail a delay in the core CagriSema combination therapy itself. Let's write this note under the slug `novo-nordisk-next-gen-pipeline-implant-cagrisema`. This is an extremely fresh, high-conviction finding.

I have completed all the research and recorded the findings in detailed notes. I will now call `finish_cycle` to complete this research cycle.

I have successfully completed this research cycle for the GLP-1 receptor agonist topic. Here is a summary of the major developments and updates recorded: ### 1. Medicare GLP-1 Bridge Program Official Launch * **Status:** Resolved Watch. The program officially went live on **July 1, 2026**. * **Key Findings:** Following the indefinite delay of the BALANCE model, CMS extended the Bridge program to an 18-month duration (ending December 31, 2027). The program covers **Wegovy**, **Zepbound**, and **Foundayo** for a flat $50 copay. While industry estimates suggested up to 20 million eligible patients, KFF analysis narrowed the eligible pool to **3.8 million Part D enrollees** once standard Part D exclusions (diabetes, OSA, MASH) and current users are filtered out. * **Operational Details:** CMS tapped **Humana** as the central claims processor. The program is projected to cost Medicare between **$1.3 billion** (10% uptake) and **$10 billion** (75% uptake) over its 18-month run. * **Note Updated:** `[[medicare-glp-1-bridge-program-50-copay]]` ### 2. Viking Therapeutics Pipeline Expansion * **New Program:** On **June 24, 2026**, Viking initiated a Phase 1 SAD study of **VK3019**, its novel dual amylin and calcitonin receptor agonist (DACRA), diversifying its pipeline into the non-GLP satiety pathway. * **VK2735 Updates:** Viking's Phase 3 **VANQUISH** program is actively enrolling, and the company remains on track to launch its Phase 3 oral VK2735 trial later in 2026. Results from its exploratory Phase 1 maintenance dosing study are anticipated in **Q3 2026**. * **Note Updated:** `[[viking-therapeutics-oral-vk2735-phase-2-venture]]` ### 3. Novo Nordisk Next-Gen Pipeline Shifts * **Ultra Long-Acting Implant:** On **July 7, 2026**, Novo Nordisk entered a development agreement with **Vivani Medical** to evaluate **NPM-139**, a miniature, subdermal semaglutide implant using Vivani’s NanoPortal technology. It is designed for once- or twice-yearly administration to solve the chronic adherence issues of weekly injections. * **CagriSema Device Trial Withdrawal:** Concurrently, Novo Nordisk withdrew a device comparability study designed to compare two CagriSema injector presentations. This does not impact the core CagriSema drug development program, which is awaiting an FDA decision in late 2026. * **New Note Created:** `[[novo-nordisk-next-gen-pipeline-implant-cagrisema]]` All active watches for Viking's Q3 maintenance readouts, oral Phase 3 trial initiation, and Amgen's tax court ruling remain in place and will be monitored in future cycles.